No Data
Shanghai hile bio-technology (603718.SH): intends to transfer 76.07% equity of Yangling Jinhai to Shanghai Haoyuan.
GrillOn November 11th, Shanghai Hile Bio-Technology (603718.SH) announced that the company held its fifth board of directors meeting on November 11, 2024, and approved the "Proposal on the Sale of Equity of Controlled Subsidiary and Related Transactions", intending to transfer 76.07% equity of Yangling Jinhai held by the company to Shanghai Haoyuan. Considering that the audited book value of the shareholders' equity of Yangling Jinhai as of August 31, 2024 was -201.6444 million yuan, and the assessed valuation of the shareholders' equity was -34.6196 million yuan, the equity transfer price for this transaction is
Risks To Shareholder Returns Are Elevated At These Prices For Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718)
Hailey Biotech: Hailey Biotech Report for the Third Quarter of 2024
Hailey Biotech 2024 Third Quarter Report
Shanghai Hile Bio-Technology (603718.SH): The net income in the first three quarters was 20.1734 million yuan, a year-on-year decrease of 72.99%.
On October 30th, Shanghai Hile Bio-Technology (603718.SH) announced that the company achieved revenue of 0.174 billion yuan in the first three quarters, a year-on-year decrease of 10.37%; net income attributable to the parent company was 20.1734 million yuan, a year-on-year decrease of 72.99%; non-net income loss was 4.4389 million yuan.
Shareholder Zhang Jianping reduced the company's shareholding by 1% at shanghai hile bio-technology (603718.SH).
Shanghai Hile Bio-Technology (603718.SH) announced that the company received a total of...
More Unpleasant Surprises Could Be In Store For Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) Shares After Tumbling 31%
